Evidence map›Paper›PMID 39155759›Full record

ArticleEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology2024

Outcomes of newly diagnosed atrial fibrillation in patients with acute coronary syndromes.

Willem Lambertus Wilbert Bor, Jaouad Azzahhafi, Nino di Maio, Niels M R van der Sangen, Ashley Verburg, Senna Rayhi, Joyce Peper, Dean R P P Chan Pin Yin, Jurrien M Ten Berg

Abstract readMulticenter Study
In one paragraph

Article in EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Age-Stratified Mortality Impact of Atrial Fibrillation in Elderly NSTEMI Patients.Journal of cardiovascular development and disease · 2026
    Article
  2. Atrial fibrillation and acute coronary syndrome.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Willem Lambertus Wilbert BorSt. Antonius Hospital, Nieuwegein, the Netherlands.
Jaouad AzzahhafiSt. Antonius Hospital, Nieuwegein, the Netherlands.
Nino di MaioSt. Antonius Hospital, Nieuwegein, the Netherlands.
Niels M R van der SangenDepartment of Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
Ashley VerburgSt. Antonius Hospital, Nieuwegein, the Netherlands.
Senna RayhiSt. Antonius Hospital, Nieuwegein, the Netherlands.
Joyce PeperSt. Antonius Hospital, Nieuwegein, the Netherlands.
Dean R P P Chan Pin YinSt. Antonius Hospital, Nieuwegein, the Netherlands.
Jurrien M Ten BergSt. Antonius Hospital, Nieuwegein, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcute coronary syndrome (ACS) is frequently accompanied by newly diagnosed atrial fibrillation (AF).

aimsWe aimed to compare the risk of major adverse cardiovascular events (MACE) in ACS patients presenting with known, newly diagnosed, or no AF.

methodsIn our multicentre, prospective registry study, we included patients with confirmed ACS. Patients are classified as having known, newly diagnosed or no AF. Newly diagnosed AF is subdivided according to the duration of the episode, time of onset, post-coronary artery bypass graft (CABG) or spontaneous occurrence, and treatment with oral anticoagulants (OAC). The primary endpoint is MACE at 1 year. Key secondary endpoints include ischaemic stroke and bleeding complications.

resultsAmongst 4,433 patients with confirmed ACS, 3,598 (81.2%) had no AF, 438 (9.9%) had newly diagnosed AF, and 397 (9.0%) had known AF. The rates of OAC treatment at discharge were 53.4% in patients with newly diagnosed AF and 89.2% in patients with known AF. After adjusting for baseline imbalances, only new AF was independently associated with increased rates of MACE, whereas known AF was not (hazard ratio [HR] 1.52, 95% confidence interval [CI]: 1.19-1.90 and HR 0.93, 95% CI: 0.70-1.23). For ACS patients with newly diagnosed AF, episodes lasting >24 hours were associated with a higher risk of MACE compared to episodes <24 hours (HR 1.99, 95% CI: 1.36-2.93). Episodes of new AF occurring post-CABG had more favourable outcomes compared to spontaneously occurring new AF (HR for MACE 0.52, 95% CI: 0.31-0.86). OAC treatment rates were higher in the new AF subcategories with higher rates of MACE and ischaemic stroke.

conclusionsNewly diagnosed AF in ACS patients was associated with higher rates of MACE and ischaemic stroke compared to ACS patients without or with known AF. Among the ACS patients with new AF, an episode lasting >24 hours was associated with worse outcomes than shorter episodes, while post-CABG occurrence of AF showed relatively better outcomes compared to spontaneously occurring AF. Only 53% of new AF patients were discharged on OAC therapy versus 89% with known AF.

Indexed as

Acute Coronary SyndromeAnticoagulantsAtrial FibrillationRegistriesAgedAged, 80 and overCoronary Artery BypassFemaleHemorrhageHumansIschemic StrokeMaleMiddle AgedProspective StudiesRisk FactorsTreatment OutcomeAnticoagulants

Identifiers

PMID39155759
PMCPMC11317829

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.